Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Ascentage Pharma (6855 HK): Placement Priced Reasonably; Pipeline Leads to Niche Market Opportunity

Ascentage Pharma (6855 HK): Olverembatinib Going Strong; Lisaftoclax Launch Will Help Gain Momentum

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ascentage-pharma-group-inter" target="_blank" data-smartkarma-citation="entities:27824:1" rel="noopener">Ascentage Pharma Group Corp (6855 HK)</a> reported revenue of RMB 574.1M in 2025, down 41.5%, because of high base effect, as the company had received intellectual property payments in 2024.</li>
<li>In 2025, the revenue from olverembatinib was RMB 435.3M (RMB 241M in 2024), up 81% YoY. Lisaftoclax, approved in July 2025, garnered RMB 70.6M in sales.</li>
<li>Ascentage is currently conducting a number of global registrational Phase III trials across its pipeline. 2026 will be crucial, losses will continue and is not expected turnaround atleast before 2027.</li>
</ul>



Ascentage Pharma Group Corp (6855 HK) reported revenue of RMB 574.1M in 2025, down 41.5%, because of high base effect, as the company had received intellectual property payments in 2024.
In 2025, the revenue from olverembatinib was RMB 435.3M (RMB 241M in 2024), up 81% YoY. Lisaftoclax, approved in July 2025, garnered RMB 70.6M in sales.
Ascentage is currently conducting a number of global registrational Phase III trials across its pipeline. 2026 will be crucial, losses will continue and is not expected turnaround atleast before 2027.


Ascentage Pharma (6855 HK): 2026 Will Be Crucial, Olverembatinib and Lisaftoclax To Gain Momentum